Novo Nordisk CEO says he’s confident about Wegovy supply, next-generation weight loss drugs
It's been a rocky few months for Novo Nordisk Prescription data from IQVIA suggests Novo's obesity King88bet Login drug Wegovy is losing ground to pesaing Zepbound from Eli Lilly . Wegovy's potential successor, CagriSema, came up short of investor expectations in a closely watched Phase 3 trial. Novo's stok has fallen more than 20% over the last year, and people feared things would get even worse when the company released fourth-quarter earnings and its 2025 outlook on Wednesday. Instead, Novo beat fourth-quarter expectations and provided a sales growth forecast between 16% and 24% - in line with the 20% Wall Street was looking for. Novo's stok rose more than 4% on Wednesday. In an interviu with CNBC, Novo Chief Executive King88bet Slot Officer Lars Fruergaard Jorgensen brushed off concerns that Novo is falling behind Lilly. "We are quite confident that as we move into the year and we'll be supplying more and more of the starter doses, we can ...